Find Luxdegalutamide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Arv-766, 2750830-09-0, Arv766, 4-(4-((1-(4-((trans-3-(4-cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-n-((s)-2,6-dioxopiperidin-3-yl)-2-fluorobenzamide, Luxdegalutamide [inn], 5bd7r933pv
Molecular Formula
C45H54FN7O6
Molecular Weight
808.0  g/mol
InChI Key
RDPPBRKNBBXPNZ-PJXMSJPKSA-N
FDA UNII
5BD7R933PV

Luxdegalutamide
Luxdegalutamide is an orally bioavailable androgen receptor (AR)-targeted protein degrader, composed of an AR ligand attached to an E3 ligase recognition moiety and utilizing the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Upon oral administration, luxdegalutamide targets and binds to the AR ligand binding domain on the AR. E3 ligase is then recruited to the AR by the E3 ligase recognition moiety of luxdegalutamide and the AR is tagged by ubiquitin. This causes ubiquitination and degradation of AR by the proteasome, and prevents the expression of AR target genes and halts AR-mediated signaling. This inhibits the proliferation of AR-overexpressing tumor cells. In addition, the degradation of the AR releases luxdegalutamide, allowing it to bind to additional AR. AR plays a key role in the proliferation of castration-resistant prostate cancer cells (CRPC). Luxdegalutamide may degrade resistance-driving point mutations of AR, including the L702H mutation associated with treatments including abiraterone.
1 2D Structure

Luxdegalutamide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[4-[[1-[4-[[3-(4-cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamoyl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-N-[(3S)-2,6-dioxopiperidin-3-yl]-2-fluorobenzamide
2.1.2 InChI
InChI=1S/C45H54FN7O6/c1-44(2)42(45(3,4)43(44)59-33-12-8-30(26-47)37(25-33)58-5)50-39(55)29-6-9-31(10-7-29)52-18-16-28(17-19-52)27-51-20-22-53(23-21-51)32-11-13-34(35(46)24-32)40(56)48-36-14-15-38(54)49-41(36)57/h6-13,24-25,28,36,42-43H,14-23,27H2,1-5H3,(H,48,56)(H,50,55)(H,49,54,57)/t36-,42?,43?/m0/s1
2.1.3 InChI Key
RDPPBRKNBBXPNZ-PJXMSJPKSA-N
2.1.4 Canonical SMILES
CC1(C(C(C1OC2=CC(=C(C=C2)C#N)OC)(C)C)NC(=O)C3=CC=C(C=C3)N4CCC(CC4)CN5CCN(CC5)C6=CC(=C(C=C6)C(=O)NC7CCC(=O)NC7=O)F)C
2.1.5 Isomeric SMILES
CC1(C(C(C1OC2=CC(=C(C=C2)C#N)OC)(C)C)NC(=O)C3=CC=C(C=C3)N4CCC(CC4)CN5CCN(CC5)C6=CC(=C(C=C6)C(=O)N[C@H]7CCC(=O)NC7=O)F)C
2.2 Other Identifiers
2.2.1 UNII
5BD7R933PV
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Arv-766

2. 2750830-09-0

3. Arv766

4. 4-(4-((1-(4-((trans-3-(4-cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-n-((s)-2,6-dioxopiperidin-3-yl)-2-fluorobenzamide

5. Luxdegalutamide [inn]

6. 5bd7r933pv

7. Schembl23536786

8. Schembl23594097

9. Gtpl12624

10. Ex-a7714

11. Nsc847604

12. At41584

13. Nsc-847604

14. Ts-09678

15. Hy-153342

16. Cs-0693933

17. 4-[4-[[1-[4-[[[trans-3-(4-cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl]a Mino]carbonyl]phenyl]-4-piperidinyl]methyl]-1-piperazinyl]-n-[(3s)-2,6-dioxo-3-piperidinyl]-2-fluoro-benzamide

18. 4-[4-[[1-[4-[[[trans-3-(4-cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl]amino]carbonyl]phenyl]-4-piperidinyl]methyl]-1-piperazinyl]-n-[(3s)-2,6-dioxo-3-piperidinyl]-2-fluorobenzamide

19. Benzamide, 4-[4-[[1-[4-[[[trans-3-(4-cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl]amino]carbonyl]phenyl]-4-piperidinyl]methyl]-1-piperazinyl]-n-[(3s)-2,6-dioxo-3-piperidinyl]-2-fluoro-

2.4 Create Date
2021-08-21
3 Chemical and Physical Properties
Molecular Weight 808.0 g/mol
Molecular Formula C45H54FN7O6
XLogP35.9
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count11
Rotatable Bond Count11
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area156
Heavy Atom Count59
Formal Charge0
Complexity1550
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Drugs in Development

read-more
read-more

Details:

Novartis obtains worldwide development & commercialization rights to ARV-766, Arvinas’ 2nd-generation PROTAC androgen receptor degrader for prostate cancer, including its preclinical AR-V7 program.


Lead Product(s): Luxdegalutamide,Abiraterone Acetate

Therapeutic Area: Oncology Brand Name: ARV-766

Study Phase: Phase I/ Phase IIProduct Type: Small molecule

Sponsor: Novartis Pharmaceuticals Corporation

Deal Size: $1,160.0 million Upfront Cash: $150.0 million

Deal Type: Licensing Agreement April 11, 2024

blank

01

Arvinas

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

Arvinas

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

Details : Novartis obtains worldwide development & commercialization rights to ARV-766, Arvinas’ 2nd-generation PROTAC androgen receptor degrader for prostate cancer, including its preclinical AR-V7 program.

Brand Name : ARV-766

Molecule Type : Small molecule

Upfront Cash : $150.0 million

April 11, 2024

blank

Details:

ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to degrade all clinically relevant resistance-driving point mutations of the androgen receptor (AR) and which being investigated forLate-line mCRPC.


Lead Product(s): Luxdegalutamide

Therapeutic Area: Oncology Brand Name: ARV-766

Study Phase: Phase I/ Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 08, 2023

blank

02

Arvinas

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

Arvinas

U.S.A
arrow
euroPLX 86 Munich
Not Confirmed

Details : ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to degrade all clinically relevant resistance-driving point mutations of the androgen receptor (AR) and which being investigated forLate-line mCRPC.

Brand Name : ARV-766

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 08, 2023

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty